In its press release dated May 20, 2025, Davita Inc. (NYSE: DVA) announced a private offering of $750 million aggregate principal amount of its senior notes due 2033. The company intends to use the net proceeds from the offering for various purposes, including repaying outstanding revolving credit facility borrowings, paying related accrued and unpaid interest, covering costs, fees, and expenses, and utilizing any remaining proceeds for general corporate purposes.
The 2033 notes are being offered to qualified institutional buyers under Rule 144A of the Securities Act of 1933, as well as to certain non-U.S. persons in compliance with Regulation S under the Securities Act.
Davita Inc. is a health care provider focused on transforming care delivery to improve the quality of life for patients globally. The company has been a leader in clinical quality and innovation for 25 years, offering comprehensive kidney care at every stage and setting along the kidney health journey.
It's important to note that this press release does not constitute an offer to sell or the solicitation of an offer to buy the 2033 notes, and there will not be any sale of the notes in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful. The market has reacted to these announcements by moving the company's shares 0.29% to a price of $145.375. Check out the company's full 8-K submission here.
